Cover Image

Interim (18F)FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma

In an attempt to identify biomarkers that can reliably predict long-term outcomes to immunotherapy in metastatic melanoma, we investigated the prognostic role of [18F]FDG PET/CT, performed at baseline and early during the course of anti-PD-1 treatment.

Saved in:
Bibliographic Details
Main Authors: Sachpekidis, Christos (Author) , Kopp-Schneider, Annette (Author) , Pan, Leyun (Author) , Papamichail, Dimitrios (Author) , Haberkorn, Uwe (Author) , Hassel, Jessica C. (Author) , Dimitrakopoulou-Strauss, Antonia (Author)
Format: Article (Journal)
Language:English
Published: 2021
In: European journal of nuclear medicine and molecular imaging
Year: 2021, Volume: 48, Issue: 6, Pages: 1932-1943
ISSN:1619-7089
DOI:10.1007/s00259-020-05137-7
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00259-020-05137-7
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00259-020-05137-7
Get full text
Author Notes:Christos Sachpekidis, Annette Kopp-Schneider, Leyun Pan, Dimitrios Papamichail, Uwe Haberkorn, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss
Description
Summary:In an attempt to identify biomarkers that can reliably predict long-term outcomes to immunotherapy in metastatic melanoma, we investigated the prognostic role of [18F]FDG PET/CT, performed at baseline and early during the course of anti-PD-1 treatment.
Item Description:Published online: 18 December 2020
Im Titel steht der Ausdruck (18 F) in eckiger Klammer, "18" ist dabei hochgestellt
Gesehen am 11.01.2024
Physical Description:Online Resource
ISSN:1619-7089
DOI:10.1007/s00259-020-05137-7

Similar Items